Search Results
Results found for "Keltic Pharma Therapeutics"
- 📰 GPCR Weekly News, May 22 to 28, 2023
Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief. Patients with Idiopathic Pulmonary Fibrosis Exscientia Business Update for First Quarter 2023 Structure Therapeutics
- Molecular basis for ligand modulation of the cannabinoid CB 1 receptor
These advances have paved the way for development of novel ligands for different therapeutic applications
- 📰 GPCR Weekly News, July 17 to July 23, 2023
GPCR Symposium on GPCRs as Therapeutic Modalities on September 22nd. Domain Therapeutics announces the European Patent Office decision to grant a patent for its proprietary
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell...
2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic
- Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic
- Viral G Protein-Coupled Receptors Encoded by β- and γ-Herpesviruses
Finally, we briefly discuss the therapeutic targeting of vGPCRs as future treatment of acute and chronic
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development of therapeutic
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
; understanding the role of DNAJC13 in GPCR trafficking could profoundly affect the development of therapeutic
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
receptor subfamily, CX3CR1 binds to its sole endogenous ligand CX3CL1, which shows notable potential as a therapeutic
- 📰 GPCR Weekly News, June 5 to 11, 2023
Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics Confo Therapeutics Enters Into Research Collaboration For GPCR-Targeting Antibody Discovery With AbCellera
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
compartments and signaling pathways associated with GPCRs holds promise for the development of novel therapeutic Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
using unique tools, and thus establishes a foundation for the development of fine-tuned aGPCR-targeted therapeutics
- G protein-coupled receptor interactions and modification of signalling involving the ghrelin ...
GHSR1a The growth hormone secretagogue receptor 1a (GHSR1a) is intriguing because of its potential as a therapeutic Initial studies of the receptor focused on the potential therapeutic ability for growth hormone (GH)
- 📰 GPCR Weekly News, January 16 to 22, 2023
Industry News Addex Provides Corporate Update And Financial Guidance Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
nanobodies with tailored specificities may expand the impact of these tools for both basic science and therapeutic
- A central alarm system that gates multi-sensory innate threat cues to the amygdala
The identification of unified innate threat pathways may provide insights into developing therapeutic
- Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5...
However, how these states impact GPCRs biological function and therapeutic targeting remains incompletely
- 📰 GPCR Weekly News, July 31 to August 6, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities' is set for September 22nd. Additional Chf 2.7 Million From Indivior In Extended Substance Use Disorder Research Collaboration Addex Therapeutics
- 📰 GPCR Weekly News, November 13 to 19, 2023
identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy Industry News OMass Therapeutics (ANDA) Litigation PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics
- 📰 GPCR Weekly News, February 6 to 12, 2023
IPO, raising $161M 3-drug combo leads to 'unprecedented' response in pancreatic cancer models Addex Therapeutics in ADX71149 Epilepsy Phase 2 Study Part 1 IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
Understanding these processes has important implications for understanding the therapeutic intervention
- Immunomodulatory Role of Neuropeptides in the Cornea
maintaining the homeostasis of the ocular surface, alterations in disease settings, and the possible therapeutic
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic
- Beyond HEK293 — Terry Hébert on iPSC-Derived GPCR Models, Live April 16,
Targeted Drug Discovery Summit brings together scientists working at the intersection of GPCR biology and therapeutic
- Lipid Modulation of a Class B GPCR: Elucidating the Modulatory Role of PI(4,5)P 2 Lipids
interacting with the Glucagon receptor (GCGR), which constitutes an important target for diabetes and obesity therapeutics
- TRPM3 in the eye and in the nervous system - from new findings to novel mechanisms
clear picture is needed to unravel TRPM3's full potential as experimental tool, diagnostic marker and therapeutic
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
Understanding these processes has important implications for understanding the therapeutic intervention

